Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : CHMD low risk below 15: Potential 50 -- Ignore unavailable to you. Want to Upgrade?

To: Dan Turner who wrote (224)	11/1/1998 10:22:00 PM
From: jfrancis	Respond to of 241

I guess I don't understand this situation. How about an update analysis Dan of how you interpret thier recent numbers, the effectiveness of their management and this selling by the CEO. What is Chronimed's realistic potential a year from now given it's current situation? Thanks jf.

To: Dan Turner who wrote (224)	11/4/1998 3:47:00 PM
From: WallStBum	Respond to of 241

Chronimed Begins Shipments of New Lasette and DiaScreen Testing Products MINNEAPOLIS, Nov. 4 /PRNewswire/ -- Chronimed Inc. (Nasdaq: CHMD - news), announced today that it has begun shipping its new Lasette(TM) Laser Lancing Device as well as its new DiaScreen(R) Reagent Strips for Urinalysis to both domestic and international customers. As previously announced on August 4, Chronimed has exclusive worldwide rights to market and sell the patent-protected Lasette laser technology products through its development and distribution agreement with Cell Robotics International, Inc. (OTC: CRII - news). The Lasette laser finger perforator is a revolutionary device designed for drawing blood from fingertips in a nearly painless manner for glucose testing. It utilizes a laser beam that penetrates the skin to obtain a capillary blood sample, instead of traditional lancets that tear the skin. In addition to minimizing immediate and residual pain, the Lasette eliminates accidental needle sticks, reduces cross contamination, eliminates sharps disposal, and can be used for testing glucose with any standard blood glucose meter. The currently available institutional model of the Lasette is designed for use in clinical settings, such as hospitals, clinics, blood banks and doctors' offices. The planned, second-generation model of the Lasette is a smaller unit designed for convenient in-home use by consumers, and is pending regulatory approval. Chronimed is now also launching the DiaScreen brand family of reagent strips for urinalysis, including the DiaScreen 10 with leukocytes and specific gravity. With the introduction of these two tests, Chronimed now offers 14 different reagent strip configurations. Urine test strips are used in physicians' offices, hospitals, and in the home to detect a variety of chronic health conditions. Easy to use and non-invasive, a single DiaScreen test strip screens 10 different clinical markers in a patient's urine. If positive, more definitive tests can be conducted to confirm a diagnosis. Chronimed Inc. is a leading integrated healthcare company specializing in diagnostic products, specialty pharmacy services, and disease management for people with chronic health conditions. The Company develops, manufactures, markets, and distributes pharmaceuticals, medical diagnostic products, and provides specialized patient management services nationwide for people with long-term chronic conditions such as HIV/AIDS, diabetes, organ transplants, and diseases treated with injectable medications. Chronimed works directly with patients, providers, and payors to improve clinical and cost-of-care outcomes. Chronimed's web site address is www.chronimed.com. As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; changes in the status of managed care contracts; and the risks described from time to time in the Company's SEC reports.